Aptevo Therapeutics Announces Second Reverse Stock Split Within 2025—APVO Consolidates Shares at 1-for-18 Ratio

Aptevo Therapeutics Inc. (APVO), a clinical-stage biotechnology company, is moving forward with a significant corporate restructuring. The company will execute a 1-for-18 reverse stock split set to take effect on December 29, 2025, at 5:01 p.m. ET, with split-adjusted trading commencing the following market open on December 30, 2025, across the Nasdaq Capital Market.

Share Consolidation Details

Under this consolidation framework, every 18 shares of common stock held by shareholders will automatically merge into a single share. The initiative is designed to compress the company’s outstanding share count from approximately 18 million shares down to roughly 1 million shares. Notably, the par value of common shares will hold steady at $0.001 per share despite the structural change.

Market Context and Stock Performance

APVO shares have experienced considerable volatility throughout 2025, trading between a low of $0.50 and a high of $109.8 during the year. Most recently, the stock declined 34.73% to close at $0.60 on Friday’s session, reflecting broader market pressures and investor sentiment toward the biotech sector.

Historical Precedent

This marks the second instance of reverse stock split activity for Aptevo Therapeutics in the current calendar year. The company previously executed a 1-for-20 reverse stock split that became effective on May 27, 2025. The sequential implementation of these corporate actions underscores ongoing efforts to reshape the company’s capital structure and market positioning.

Reverse stock splits are commonly employed by companies to address various strategic objectives, including compliance with exchange listing standards and improving share price perception among investors. For Aptevo shareholders, it remains essential to monitor subsequent trading activity and corporate developments to assess the long-term implications of these structural modifications.

Disclaimer: These statements reflect factual corporate actions and do not constitute investment advice or recommendations regarding Aptevo Therapeutics securities.